Los efectos secundarios gastrointestinales del semaglutide, especialmente vmitos y diarrea, pueden llevar a deshidratacin, lo que potencialmente aumenta el riesgo de lesin renal, particularmente si se usan AINEs
We dont yet know: So while the idea of low-dose Wegovy for energy, appetite control, or menopause support is interesting, its not backed by strong science (at least not yet)
Novo Nordisk has published phase 3 data showing that a dual therapy comprising cagrilintide and semaglutide (the GLP-1 agonist in Wegovy), coupled with lifestyle interventions, achieved an average of 13.7% weight loss in patients with type 2 diabetes, who are also overweight or obese, over a period of 68 weeks 8
These medications work by modulating appetite-regulating hormones, and when you stop taking them, those hormones revert to their pre-treatment patterns